Cargando…

A Significance of High Prevalence of Diabetes and Hypertension in Severe COVID-19 Patients

Detalles Bibliográficos
Autor principal:	Yanai, Hidekatsu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295548/ https://www.ncbi.nlm.nih.gov/pubmed/32587655 http://dx.doi.org/10.14740/jocmr4218

Ejemplares similares

Significant Correlations of SARS-CoV-2 Infection With Prevalence of Overweight/Obesity and Mean Body Mass Index in the SARS-CoV-2 Endemic Countries
por: Yanai, Hidekatsu
Publicado: (2020)

Bofutsushosan Significantly Ameliorated Betamethasone-Induced Cushing’s Syndrome
por: Yanai, Hidekatsu
Publicado: (2018)

Adiposity is the Crucial Enhancer of COVID-19
por: Yanai, Hidekatsu
Publicado: (2020)

A Different Effect of an Orexin Receptor Antagonist on Metabolic Parameters Between Diabetic Patients and Non-Diabetic Patients
por: Yanai, Hidekatsu, et al.
Publicado: (2018)

Does Metformin Assist New Anti-Diabetic Drugs to Succeed?
por: Kastuyama, Hisayuki, et al.
Publicado: (2019)

Habit of Bathing or Showering Is Beneficially Associated With Body Weight and Abdominal Circumference in Patients With Type 2 Diabetes
por: Katsuyama, Hisayuki, et al.
Publicado: (2018)

Understanding of Diabetic Dyslipidemia by Using the Anion-Exchange High Performance Liquid Chromatography Data
por: Yanai, Hidekatsu, et al.
Publicado: (2016)

Acute Effects of Preventing Heart Failure by Sodium-Glucose Cotransporter 2 Inhibitors
por: Yanai, Hidekatsu
Publicado: (2021)

A Possible Mechanism for Renoprotective Effect of Sodium-Glucose Cotransporter 2 Inhibitor: Elevation of Erythropoietin Production
por: Yanai, Hidekatsu, et al.
Publicado: (2017)

Severe Thrombocytopenia Due to Repaglinide in a Patient With Type 2 Diabetes
por: Katsuyama, Hisayuki, et al.
Publicado: (2013)

An Influence of the Estimated Glomerular Filtration Rate on Improvement in Metabolic Parameters by Sodium-Glucose Cotransporter 2 Inhibitors
por: Katsuyama, Hisayuki, et al.
Publicado: (2016)

Which Nutritional Factors Are Good for HDL?
por: Yanai, Hidekatsu, et al.
Publicado: (2018)

What Properties of Sodium-Glucose Cotransporter 2 Inhibitors Determine the Improvement in Hemoglobin A1c and Body Weight?
por: Yanai, Hidekatsu, et al.
Publicado: (2017)

High prevalence of heterotopic ossification in critically ill patients with severe COVID-19
por: Stoira, Elisa, et al.
Publicado: (2021)

The Application of Sodium-Glucose Cotransporter 2 Inhibitors to Chronic Kidney Disease Stage 4
por: Koguchi, Ayako, et al.
Publicado: (2017)

Which Factor Determines the Duration Required for Relief of Glucotoxicity by the Intensive Insulin Therapy?
por: Yanai, Hidekatsu, et al.
Publicado: (2018)

Renoprotective Effect of Xanthine Oxidase Inhibitor, Topiroxostat
por: Katsuyama, Hisayuki, et al.
Publicado: (2019)

The Possible Mechanisms for Improvement of Liver Function due to Sodium-Glucose Cotransporter-2 Inhibitors
por: Yanai, Hidekatsu, et al.
Publicado: (2019)

Clinically significant portal hypertension in cirrhosis patients with COVID-19: Clinical characteristics and outcomes
por: Liu, Furong, et al.
Publicado: (2020)

A Possible Exquisite Crosstalk of Urate Transporter 1 With Other Urate Transporters for Chronic Kidney Disease and Cardiovascular Disease Induced by Dotinurad
por: Yanai, Hidekatsu, et al.
Publicado: (2023)

An Effective Insulin Therapy in Combination With Sodium-Glucose Cotransporter 2 Inhibitors
por: Yanai, Hidekatsu, et al.
Publicado: (2019)

‘High prevalence of heterotopic ossification in critically ill patients with severe COVID-19’ – Author's reply
por: Stoira, Elisa, et al.
Publicado: (2021)

CA-125 Significance in Cirrhosis and Correlation with Disease Severity and Portal Hypertension
por: Collazos, Julio
Publicado: (2018)

Re: “High prevalence of heterotopic ossification in critically ill patients with severe COVID-19” by Stoira et al.
por: de l’Escalopier, Nicolas, et al.
Publicado: (2021)

COVID-19 is more severe in patients with hypertension; ACEI/ARB treatment does not influence clinical severity and outcome
por: Hu, Jianhua, et al.
Publicado: (2020)

Prevalence and clinical significance of relative bradycardia at hospital admission in patients with coronavirus disease 2019 (COVID-19)
por: Oliva, Alessandra, et al.
Publicado: (2021)

Comment on: Tsiakou et al. Arterial Stiffness Is Inversely Related to Plasma Adiponectin Levels in Young Normotensive Patients With Type 1 Diabetes. Diabetes Care 2013;36:734–736
por: Hamasaki, Hidetaka, et al.
Publicado: (2013)

Streptococcal Infection Can Be the Trigger for Thyroid Storm
por: Hakoshima, Mariko, et al.
Publicado: (2019)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA in peritoneal fluid of coronavirus disease 2019 (COVID-19) patients—Prevalence and significance
por: Seeliger, Barbara, et al.
Publicado: (2021)

Diabetes and severity of COVID-19: What is the link?
por: Pitocco, D., et al.
Publicado: (2020)

Significant impact of COVID-19 on organ donation and transplantation in a low-prevalence country: Australia
por: Chadban, Steven J., et al.
Publicado: (2020)

A Significant Effect of Oral Semaglutide on Cardiovascular Risk Factors in Patients With Type 2 Diabetes
por: Yanai, Hidekatsu, et al.
Publicado: (2022)

No adequate evidence indicating hypertension as an independent risk factor for COVID-19 severity
por: Li, Gerui, et al.
Publicado: (2020)

A Significant Increase of Estimated Glomerular Filtration Rate After Switching From Fenofibrate to Pemafibrate in Type 2 Diabetic Patients
por: Yanai, Hidekatsu, et al.
Publicado: (2021)

Diabetic neuropathy: a risk factor for severe COVID-19?
por: Pitocco, Dario, et al.
Publicado: (2021)

Metabolic Syndrome and COVID-19
por: Yanai, Hidekatsu
Publicado: (2020)

Letter to the Editor regarding “Could pulmonary arterial hypertension patients be at lower risk from severe COVID-19?”
por: Fernandes, Timothy M., et al.
Publicado: (2020)

Angiotensin converting enzyme inhibitors and angiotensin receptor blockers improved the outcome of patients with severe COVID-19 and hypertension
por: Meng, Xiao, et al.
Publicado: (2020)

Management of hypertension in COVID-19
por: Antwi-Amoabeng, Daniel, et al.
Publicado: (2020)

Ca(2+)/cAMP ratio: An inflammatory index for diabetes, hypertension, and COVID-19
por: Bergantin, Leandro
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_55fm5r5j5f9ds6rusd0kae9dqa